Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

2.

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F.

Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.

3.

methGraph: a genome visualization tool for PCR-based methylation assays.

Lefever S, Hoebeeck J, Pattyn F, Tusnády G, De Paepe A, Speleman F, Arányi T, Vandesompele J.

Epigenetics. 2010 Feb 16;5(2):159-63. Epub 2010 Feb 11.

4.

The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P, Vermeulen J, Vandesompele J, Speleman F.

Genome Med. 2009 Jul 27;1(7):74. doi: 10.1186/gm74.

5.

Chromosome 3p microsatellite allelotyping in neuroblastoma: a report on the technical hurdles.

Hoebeeck J, De Wilde B, Michels E, Combaret V, Yigit N, De Smet E, Van Roy N, Stanbridge E, Ru N, Laureys G, De Paepe A, Speleman F, Vandesompele J.

Cancer Invest. 2009 Oct;27(8):857-68. doi: 10.1080/07357900902769731.

PMID:
19544108
6.

Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.

Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, Hoyoux C, Laureys G, De Paepe A, Speleman F, Vandesompele J.

Cancer Lett. 2009 Jan 18;273(2):336-46. doi: 10.1016/j.canlet.2008.08.019. Epub 2008 Sep 25.

PMID:
18819746
7.

CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23.

Michels E, Hoebeeck J, De Preter K, Schramm A, Brichard B, De Paepe A, Eggert A, Laureys G, Vandesompele J, Speleman F.

BMC Cancer. 2008 Jun 17;8:173. doi: 10.1186/1471-2407-8-173.

8.

ArrayCGH-based classification of neuroblastoma into genomic subgroups.

Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, De Paepe A, Versteeg R, Eggert A, Laureys G, Van Roy N, Speleman F.

Genes Chromosomes Cancer. 2007 Dec;46(12):1098-108.

PMID:
17823929
9.

[New insights into the genetic basis of neuroblastoma].

Speleman F, De Preter K, Hoebeeck J, Van Roy N, Vandesompele J.

Verh K Acad Geneeskd Belg. 2007;69(4):167-96. Review. Dutch.

PMID:
17821957
10.
11.

Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints.

Michels E, Vandesompele J, Hoebeeck J, Menten B, De Preter K, Laureys G, Van Roy N, Speleman F.

Cytogenet Genome Res. 2006;115(3-4):273-82.

PMID:
17124410
12.

High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors.

Hoebeeck J, Michels E, Menten B, Van Roy N, Eggert A, Schramm A, De Preter K, Yigit N, De Smet E, De Paepe A, Laureys G, Vandesompele J, Speleman F.

Int J Cancer. 2007 Feb 1;120(3):533-8.

PMID:
17096344
13.

methBLAST and methPrimerDB: web-tools for PCR based methylation analysis.

Pattyn F, Hoebeeck J, Robbrecht P, Michels E, De Paepe A, Bottu G, Coornaert D, Herzog R, Speleman F, Vandesompele J.

BMC Bioinformatics. 2006 Nov 9;7:496.

14.

The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma.

Hoebeeck J, Vandesompele J, Nilsson H, De Preter K, Van Roy N, De Smet E, Yigit N, De Paepe A, Laureys G, Påhlman S, Speleman F.

Int J Cancer. 2006 Aug 1;119(3):624-9.

PMID:
16506218
15.

Rapid detection of VHL exon deletions using real-time quantitative PCR.

Hoebeeck J, van der Luijt R, Poppe B, De Smet E, Yigit N, Claes K, Zewald R, de Jong GJ, De Paepe A, Speleman F, Vandesompele J.

Lab Invest. 2005 Jan;85(1):24-33.

16.

No evidence for involvement of SDHD in neuroblastoma pathogenesis.

De Preter K, Vandesompele J, Hoebeeck J, Vandenbroecke C, Smet J, Nuyts A, Laureys G, Combaret V, Van Roy N, Roels F, Van Coster R, Praet M, De Paepe A, Speleman F.

BMC Cancer. 2004 Aug 24;4:55.

17.

Application of laser capture microdissection in genetic analysis of neuroblastoma and neuroblastoma precursor cells.

De Preter K, Vandesompele J, Heimann P, Kockx MM, Van Gele M, Hoebeeck J, De Smet E, Demarche M, Laureys G, Van Roy N, De Paepe A, Speleman F.

Cancer Lett. 2003 Jul 18;197(1-2):53-61. Review.

PMID:
12880960
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk